ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS20 MARCH 2025 at 15.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities
20 mars, 14:30
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS20 MARCH 2025 at 15.30 EET
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 19 March 2025 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
% of shares and voting rights (total of point A) | % of shares and voting rights through financial instruments (total of point B) | Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
Resulting situation on the date on which threshold was crossed or reached | 5.03% sharesBelow 5% voting rights | 0.00% sharesBelow 5% voting rights | 5.03% sharesBelow 5% voting rights | 141,134,278 shares763,427,275 voting rights |
Position of previous notification (if applicable) | Below 5% sharesBelow 5% voting rights | Below 5% sharesBelow 5% voting rights | Below 5% sharesBelow 5% voting rights |
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
Class/type of sharesISIN code | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
FI0009014377 | 7,105,295 sharesBelow 5% voting rights | 5.03% sharesBelow 5% voting rights | ||
POINT A SUBTOTAL | 7,105,295 sharesBelow 5% voting rights | 5.03% sharesBelow 5% voting rights |
Point B: Financial instruments according to SMA 9:6a:
Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
Securities Lent | N/A | N/A | Physical | 5,622 sharesBelow 5% voting rights | 0.00% sharesBelow 5% voting rights |
POINT B SUBTOTAL | 5,622 sharesBelow 5% voting rights | 0.00% sharesBelow 5% voting rights |
Orion Corporation
Liisa HurmePresident and CEO | Olli HuotariEVP, Corporate Functions |
Contact person:Tuukka Hirvonen, Investor Relations, Orion Corporationtel. +358 10 426 2721
Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandwww.orionpharma.com
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS20 MARCH 2025 at 15.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities
20 mars, 14:30
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS20 MARCH 2025 at 15.30 EET
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 19 March 2025 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
% of shares and voting rights (total of point A) | % of shares and voting rights through financial instruments (total of point B) | Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
Resulting situation on the date on which threshold was crossed or reached | 5.03% sharesBelow 5% voting rights | 0.00% sharesBelow 5% voting rights | 5.03% sharesBelow 5% voting rights | 141,134,278 shares763,427,275 voting rights |
Position of previous notification (if applicable) | Below 5% sharesBelow 5% voting rights | Below 5% sharesBelow 5% voting rights | Below 5% sharesBelow 5% voting rights |
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
Class/type of sharesISIN code | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
FI0009014377 | 7,105,295 sharesBelow 5% voting rights | 5.03% sharesBelow 5% voting rights | ||
POINT A SUBTOTAL | 7,105,295 sharesBelow 5% voting rights | 5.03% sharesBelow 5% voting rights |
Point B: Financial instruments according to SMA 9:6a:
Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
Securities Lent | N/A | N/A | Physical | 5,622 sharesBelow 5% voting rights | 0.00% sharesBelow 5% voting rights |
POINT B SUBTOTAL | 5,622 sharesBelow 5% voting rights | 0.00% sharesBelow 5% voting rights |
Orion Corporation
Liisa HurmePresident and CEO | Olli HuotariEVP, Corporate Functions |
Contact person:Tuukka Hirvonen, Investor Relations, Orion Corporationtel. +358 10 426 2721
Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandwww.orionpharma.com
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
Fortnox-budet
Riksbanken
Nibe
Analyser
Fortnox-budet
Riksbanken
Nibe
Analyser
1 DAG %
Senast
Fortnox
Idag, 14:18
Fortnox-budet: Högmod före fall?
OMX Stockholm 30
1 DAG %
Senast
2 487,71
-992x558.png&w=3840&q=75)
-160x160.jpg&w=3840&q=75)
